- World Pharma News Home » Product » Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
(a free service delivered by FeedBurner)
Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX), announced that it and Mylan Inc. (NYSE: MYL) have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic(TM) (nebivolol), which is currently approved in the United States for the treatment of hypertension. The companies have agreed that Forest will assume Mylan's commercial rights for Bystolic in the United States and Canada including, but not limited to, the elimination of Mylan's option to co-promote the product. Forest will be responsible for all future Bystolic development expenses as well as all sales and marketing expenses for the product.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments